Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Leukemia, Myeloid, Acute 2Myelodysplastic Syndromes 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Biphenotypic, Acute 1Blast Crisis 1

Interventions

fludarabine 10Specimen Handling 8Cytarabine 8Cyclophosphamide 8Biopsy 8fludarabine phosphate 7Whole-Body Irradiation 7venetoclax 6Injections 6Busulfan 6Azacitidine 6Mycophenolic Acid 5Melphalan 5Granulocyte Colony-Stimulating Factor 5Filgrastim 5decitabine and cedazuridine drug combination 4X-Rays 4Tacrolimus 4Stem Cell Transplantation 4Cyclosporine 4CPX-351 4Peripheral Blood Stem Cell Transplantation 3Magnetic Resonance Spectroscopy 3Idarubicin 3Decitabine 3treosulfan 2ruxolitinib 2luspatercept 2ivosidenib 2gilteritinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Myelodysplastic Syndromes × midostaurin × 30 days × Clear all
NCT02115295 2026-05-20

Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia

M.D. Anderson Cancer Center

Phase 2 Recruiting
508 enrolled
MyeloidOther hematologic neoplasm

Blast Crisis, Myelodysplastic Syndromes, Leukemia, Biphenotypic, Acute, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡